Gain Therapeutics Inc

GANX

NASDAQ. Currency in USD

2.97 -0.01 ( -0.34% )

Real time prices: December 19

Market Cap.
35.29M
Beta (5Y monthly)
-
Price/Earnings
-
EPS (TTM)
-1.34
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
90,021
1y Target Est.
7.80
Day's Range
2.87
-
3.01
52 Week's Range
2.33
-
6.70

Historical Summary

Performance
EPS growth
Share Buybacks

About Gain Therapeutics Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.gaintherapeutics.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
11.88M
Employees
25
Address
4800 Montgomery Lane, Bethesda, MD, United States, 20814
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Latest news

Expert Ratings for Gain Therapeutics
Expert Ratings for Gain Therapeutics

Analysts have provided the following ratings for Gain Therapeutics (NASDAQ:GANX) within the last quarter: Bullish...
By Benzinga - 7 weeks ago

Analyst Ratings for Gain Therapeutics
Analyst Ratings for Gain Therapeutics

Over the past 3 months, 4 analysts have published their opinion on Gain Therapeutics (NASDAQ:GANX)...
By Benzinga - 7 weeks ago

Medtronic To $85? Plus Oppenheimer Slashes PT On This Stock By 67%
Medtronic To $85? Plus Oppenheimer Slashes PT On This Stock By 67%

Barclays cut Medtronic plc (NYSE: MDT) price target from $90 to $85. Medtronic shares gained...
By Benzinga - 9 weeks ago

Heska To $165? Plus BTIG Cuts PT On This Stock By 67%
Heska To $165? Plus BTIG Cuts PT On This Stock By 67%

BTIG cut the price target on Gain Therapeutics, Inc. (NASDAQ: GANX) from $30 to $10....
By Benzinga - 11 weeks ago

AMD To Rally Around 39%? Here Are 5 Other Price Target Changes For Monday
AMD To Rally Around 39%? Here Are 5 Other Price Target Changes For Monday

Baird raised Advanced Micro Devices, Inc. (NASDAQ: AMD) price target from $65 to $100. ....
By Benzinga - 11 weeks ago

Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates

Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.39% and 100%, respectively, for...
By Zacks Investment Research - 11 weeks ago

Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update
Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update

Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small...
By GlobeNewswire Inc. - 11 weeks ago

Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates

Century Therapeutics, Inc. (IPSC) delivered earnings and revenue surprises of 10.17% and 42.11%, respectively, for...
By Zacks Investment Research - 11 weeks ago